Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea.

Autor: Boof ML; Idorsia Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland. Electronic address: marielaure.boof@idorsia.com., Ufer M; Idorsia Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland., Fietze I; Advanced Sleep Research, Berlin, Germany., Pépin JL; HP2 Laboratory, INSERM U1042, Grenoble Alpes University Hospital and EFCR Laboratory, Thorax and Vessels Division, Grenoble, France., Guern AS; Idorsia Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland., Lemoine V; Idorsia Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland., Dingemanse J; Idorsia Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland.

Publikováno v: Sleep medicine [Sleep Med] 2022 Apr; Vol. 92, pp. 4-11. Date of Electronic Publication: 2022 Feb 12.

Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea.

Autor: Boof ML; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Lederer K; Advanced Sleep Research GmbH, Berlin, Germany., Fietze I; Advanced Sleep Research GmbH, Berlin, Germany., Ufer M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Publikováno v: Sleep [Sleep] 2021 Jun 11; Vol. 44 (6).

Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P 1 receptor modulator in healthy subjects.

Autor: Boof ML; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., van Lier JJ; PRA Health Sciences, Groningen, The Netherlands., English S; Pharmaron ABS (former Xceleron), Germantown, MD, USA., Fischer H; A&M Labor für Analytik und Metabolismusforschung Service GmbH, Bergheim, Germany., Ufer M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.

Publikováno v: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2020 Aug; Vol. 50 (8), pp. 947-956. Date of Electronic Publication: 2020 Mar 09.

Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies.

Autor: Boof ML; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland. marielaure.boof@idorsia.com., Alatrach A; Clinical Research Services Kiel GmbH, Lornsenstrasse 7, 24105, Kiel, Germany., Ufer M; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland., Dingemanse J; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland.

Publikováno v: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2019 Feb; Vol. 75 (2), pp. 195-205. Date of Electronic Publication: 2018 Oct 04.